Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications.
Robert Mownn, PharmD
Advertisement
Articles by Robert Mownn, PharmD
An emerging focus is aligning targeted, safe, and effective therapies with patient goals.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC
3
Expert Discusses Logistical Considerations and Future Research Needs for Radiopharmaceuticals
4
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
5
